APO Research
Talk to an analyst

APO RESEARCH · REPORT

Complement Targeted Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Complement Targeted Therapeutics Market Outlook and Growth Opportunities 2026

20 December 2025196 pages

Choose your research edition.

Industry ResearchComplement Targeted Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Complement Targeted Therapeutics Industry Growth and Trends Forecast to 203289 pages · $3,450 USDMarket StructureGlobal Complement Targeted Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Complement Targeted Therapeutics Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Complement Targeted Therapeutics Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Complement Targeted Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Complement Targeted Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Complement Targeted Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Complement Targeted Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Complement Targeted Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Complement Targeted Therapeutics market include Alexion Pharmaceuticals, Allergan, Creative Biolabs, AbbVie, Pfizer, Merck and Novartis AG, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Complement Targeted Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Complement Targeted Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Complement Targeted Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Complement Targeted Therapeutics market.

Complement Targeted Therapeutics Segment by Company

Alexion Pharmaceuticals

Allergan

Creative Biolabs

AbbVie

Pfizer

Merck

Novartis AG

Complement Targeted Therapeutics Segment by Type

Paroxysmal Nocturnal Haemoglobinuria

Atypical Haemolytic Uraemic Syndrome (AHUS)

Complement Targeted Therapeutics Segment by Application

Retail Pharamacies

Online Pharmacies

Hospital Pharmacies

Complement Targeted Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Complement Targeted Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Complement Targeted Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Complement Targeted Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Complement Targeted Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Complement Targeted Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Complement Targeted Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Complement Targeted Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Complement Targeted Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Complement Targeted Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Complement Targeted Therapeutics industry.

Chapter 3: Detailed analysis of Complement Targeted Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Complement Targeted Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Complement Targeted Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Complement Targeted Therapeutics Industry Trends Table 2. Complement Targeted Therapeutics Industry Drivers Table 3. Complement Targeted Therapeutics Industry Opportunities and Challenges Table 4. Complement Targeted Therapeutics Industry Restraints Table 5. Global Complement Targeted Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Complement Targeted Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Complement Targeted Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Complement Targeted Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Complement Targeted Therapeutics Company, Product Type & Application Table 10. Global Complement Targeted Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Complement Targeted Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Paroxysmal Nocturnal Haemoglobinuria Table 15. Significant Companies of Atypical Haemolytic Uraemic Syndrome (AHUS) Table 16. Global Complement Targeted Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Complement Targeted Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Complement Targeted Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Complement Targeted Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Complement Targeted Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Retail Pharamacies Table 22. Significant Companies of Online Pharmacies Table 23. Significant Companies of Hospital Pharmacies Table 24. Global Complement Targeted Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Complement Targeted Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Complement Targeted Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Complement Targeted Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Complement Targeted Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Complement Targeted Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Complement Targeted Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Complement Targeted Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Complement Targeted Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Complement Targeted Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Complement Targeted Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Complement Targeted Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Complement Targeted Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Complement Targeted Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Complement Targeted Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Alexion Pharmaceuticals Company Information Table 40. Alexion Pharmaceuticals Business Overview Table 41. Alexion Pharmaceuticals Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Alexion Pharmaceuticals Complement Targeted Therapeutics Product Portfolio Table 43. Alexion Pharmaceuticals Recent Development Table 44. Allergan Company Information Table 45. Allergan Business Overview Table 46. Allergan Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Allergan Complement Targeted Therapeutics Product Portfolio Table 48. Allergan Recent Development Table 49. Creative Biolabs Company Information Table 50. Creative Biolabs Business Overview Table 51. Creative Biolabs Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Creative Biolabs Complement Targeted Therapeutics Product Portfolio Table 53. Creative Biolabs Recent Development Table 54. AbbVie Company Information Table 55. AbbVie Business Overview Table 56. AbbVie Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. AbbVie Complement Targeted Therapeutics Product Portfolio Table 58. AbbVie Recent Development Table 59. Pfizer Company Information Table 60. Pfizer Business Overview Table 61. Pfizer Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Pfizer Complement Targeted Therapeutics Product Portfolio Table 63. Pfizer Recent Development Table 64. Merck Company Information Table 65. Merck Business Overview Table 66. Merck Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Merck Complement Targeted Therapeutics Product Portfolio Table 68. Merck Recent Development Table 69. Novartis AG Company Information Table 70. Novartis AG Business Overview Table 71. Novartis AG Complement Targeted Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Novartis AG Complement Targeted Therapeutics Product Portfolio Table 73. Novartis AG Recent Development Table 74. Research Programs/Design for This Report Table 75. Authors List of This Report Table 76. Secondary Sources Table 77. Primary Sources List of Figures Figure 1. Complement Targeted Therapeutics Product Image Figure 2. Global Complement Targeted Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Complement Targeted Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Complement Targeted Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Paroxysmal Nocturnal Haemoglobinuria Image Figure 8. Atypical Haemolytic Uraemic Syndrome (AHUS) Image Figure 9. Global Complement Targeted Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Complement Targeted Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Complement Targeted Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Retail Pharamacies Image Figure 13. Online Pharmacies Image Figure 14. Hospital Pharmacies Image Figure 15. Global Complement Targeted Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Complement Targeted Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Complement Targeted Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Complement Targeted Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Complement Targeted Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Complement Targeted Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Complement Targeted Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Complement Targeted Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Complement Targeted Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Complement Targeted Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Complement Targeted Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Complement Targeted Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Complement Targeted Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Complement Targeted Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Complement Targeted Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Paroxysmal Nocturnal Haemoglobinuria
  • Atypical Haemolytic Uraemic Syndrome (AHUS)
Applications
  • Retail Pharamacies
  • Online Pharmacies
  • Hospital Pharmacies
Companies covered
  • Alexion Pharmaceuticals
  • Allergan
  • Creative Biolabs
  • AbbVie
  • Pfizer
  • Merck
  • Novartis AG

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Complement Targeted Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Complement Targeted Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Complement Targeted Therapeutics Market Dynamics
  1. 2.1 Complement Targeted Therapeutics Industry Trends
  2. 2.2 Complement Targeted Therapeutics Industry Drivers
  3. 2.3 Complement Targeted Therapeutics Industry Opportunities and Challenges
  4. 2.4 Complement Targeted Therapeutics Industry Restraints
3 Complement Targeted Therapeutics Market by Company
  1. 3.1 Global Complement Targeted Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Complement Targeted Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Complement Targeted Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Complement Targeted Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Complement Targeted Therapeutics Company Product Type and Application
  6. 3.6 Global Complement Targeted Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Complement Targeted Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Complement Targeted Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Complement Targeted Therapeutics Market by Type
  1. 4.1 Complement Targeted Therapeutics Type Introduction
  2. 4.1.1 Paroxysmal Nocturnal Haemoglobinuria
  3. 4.1.2 Atypical Haemolytic Uraemic Syndrome (AHUS)
  4. 4.2 Global Complement Targeted Therapeutics Sales Value by Type
  5. 4.2.1 Global Complement Targeted Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Complement Targeted Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Complement Targeted Therapeutics Sales Value Share by Type (2021-2032)
5 Complement Targeted Therapeutics Market by Application
  1. 5.1 Complement Targeted Therapeutics Application Introduction
  2. 5.1.1 Retail Pharamacies
  3. 5.1.2 Online Pharmacies
  4. 5.1.3 Hospital Pharmacies
  5. 5.2 Global Complement Targeted Therapeutics Sales Value by Application
  6. 5.2.1 Global Complement Targeted Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Complement Targeted Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Complement Targeted Therapeutics Sales Value Share by Application (2021-2032)
6 Complement Targeted Therapeutics Regional Value Analysis
  1. 6.1 Global Complement Targeted Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Complement Targeted Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Complement Targeted Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Complement Targeted Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Complement Targeted Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Complement Targeted Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Complement Targeted Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Complement Targeted Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Complement Targeted Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Complement Targeted Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Complement Targeted Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Complement Targeted Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Complement Targeted Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Complement Targeted Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Complement Targeted Therapeutics Country-level Value Analysis
  1. 7.1 Global Complement Targeted Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Complement Targeted Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Complement Targeted Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Complement Targeted Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Complement Targeted Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Complement Targeted Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Complement Targeted Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Alexion Pharmaceuticals
  2. 8.1.1 Alexion Pharmaceuticals Company Information
  3. 8.1.2 Alexion Pharmaceuticals Business Overview
  4. 8.1.3 Alexion Pharmaceuticals Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alexion Pharmaceuticals Complement Targeted Therapeutics Product Portfolio
  6. 8.1.5 Alexion Pharmaceuticals Recent Developments
  7. 8.2 Allergan
  8. 8.2.1 Allergan Company Information
  9. 8.2.2 Allergan Business Overview
  10. 8.2.3 Allergan Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Allergan Complement Targeted Therapeutics Product Portfolio
  12. 8.2.5 Allergan Recent Developments
  13. 8.3 Creative Biolabs
  14. 8.3.1 Creative Biolabs Company Information
  15. 8.3.2 Creative Biolabs Business Overview
  16. 8.3.3 Creative Biolabs Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Creative Biolabs Complement Targeted Therapeutics Product Portfolio
  18. 8.3.5 Creative Biolabs Recent Developments
  19. 8.4 AbbVie
  20. 8.4.1 AbbVie Company Information
  21. 8.4.2 AbbVie Business Overview
  22. 8.4.3 AbbVie Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AbbVie Complement Targeted Therapeutics Product Portfolio
  24. 8.4.5 AbbVie Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Complement Targeted Therapeutics Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Merck
  32. 8.6.1 Merck Company Information
  33. 8.6.2 Merck Business Overview
  34. 8.6.3 Merck Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Merck Complement Targeted Therapeutics Product Portfolio
  36. 8.6.5 Merck Recent Developments
  37. 8.7 Novartis AG
  38. 8.7.1 Novartis AG Company Information
  39. 8.7.2 Novartis AG Business Overview
  40. 8.7.3 Novartis AG Complement Targeted Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Novartis AG Complement Targeted Therapeutics Product Portfolio
  42. 8.7.5 Novartis AG Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst